Colleges
Jagdeep Nanchahal
Professor of Hand, Plastic and Reconstructive Surgery
Jagdeep undertook his PhD, funded by the MRC, whilst a medical student in London and trained as a reconstructive plastic surgeon. His research is focussed on identifying novel therapeutic targets for reducing fibrosis and promoting tissue regeneration, and translating his findings through to clinical trials.
In 2013 his group identified TNF as therapeutic target for Dupuytren’s disease, a common fibrotic condition of the hand. He was chief investigator for a phase 2a followed by a recently completed phase 2b clinical by the Wellcome Trust and Department of Health and 180 Life Sciences to assess the efficacy of local administration of anti-TNF in patients with early stage Dupuytren’s disease. The trials showed that intranodular injections of adalimumab downregulate myofibroblast phenotype and lead to softening and decrease in size of the nodules of early-stage disease, which continue for up to 9 months after the final injection. He is co-chief investigator for a trial of anti-TNF for early stage, pain-predominant frozen shoulder and co-applicant on a trial led by Prof Matt Costa at the Kadoorie Centre of anti-TNF for preventing delirium in patients undergoing surgery for hip fractures.
His group has also identified a novel mechanism for promoting repair and regeneration of multiple tissues by targeting endogenous stem cells and is developing HMGB1 as a therapeutic with funding from a Wellcome Trust Innovator Award.
He is a proponent of evidence-based medicine and was the only plastic surgery member of the NICE Guidance Development Groups on complex and non-complex fractures.
Key publications
-
Anti-tumour necrosis factor therapy for early-stage Dupuytren's disease (RIDD): a phase 2b, randomised, double-blind, placebo-controlled trial
Journal article
Nanchahal J. et al, (2022), The Lancet Rheumatology
-
Fully reduced HMGB1 accelerates the regeneration of multiple tissues by transitioning stem cells to GAlert.
Journal article
Lee G. et al, (2018), Proc Natl Acad Sci U S A, 115, E4463 - E4472
-
Strategies to overcome the hurdles to treat fibrosis, a major unmet clinical need
Journal article
Nanchahal J. and Hinz B., (2016), Proceedings of the National Academy of Sciences of USA, 113, 7291 - 7293
-
Anti-Tumour Necrosis Factor Therapy for Dupuytren's Disease: A Randomised Dose Response Proof of Concept Phase 2a Clinical Trial.
Journal article
Nanchahal J. et al, (2018), EBioMedicine, 33, 282 - 288
-
Alarmins: awaiting a clinical response.
Journal article
Chan JK. et al, (2012), J Clin Invest, 122, 2711 - 2719
-
Treatment of rheumatoid tenosynovitis with cytokine inhibitors.
Journal article
Jain A. et al, (2002), Lancet, 360, 1565 - 1566
-
Unraveling the signaling pathways promoting fibrosis in Dupuytren's disease reveals TNF as a therapeutic target.
Journal article
Verjee LS. et al, (2013), Proc Natl Acad Sci U S A, 110, E928 - E937
-
Identification of TNFR2 and IL-33 as therapeutic targets in localized fibrosis.
Journal article
Izadi D. et al, (2019), Sci Adv, 5
-
Identifying collagen VI as a target of fibrotic diseases regulated by CREBBP/EP300.
Journal article
Williams LM. et al, (2020), Proc Natl Acad Sci U S A, 117, 20753 - 20763
-
Cellular census of human fibrosis defines functionally distinct stromal cell types and states.
Journal article
Layton TB. et al, (2020), Nat Commun, 11
-
Effect of Incisional Negative Pressure Wound Therapy vs Standard Wound Dressing on Deep Surgical Site Infection After Surgery for Lower Limb Fractures Associated With Major Trauma: The WHIST Randomized Clinical Trial.
Journal article
Costa ML. et al, (2020), JAMA, 323, 519 - 526
-
Timing of antibiotic administration, wound debridement, and the stages of reconstructive surgery for open long bone fractures of the upper and lower limbs.
Journal article
Chan JK-K. et al, (2022), Cochrane Database Syst Rev, 4
Recent publications
-
PERI-operative biologic DMARD management: Stoppage or COntinuation during orthoPaEdic operations (the PERISCOPE trial) - a study protocol for a pragmatic, UK multicentre, superiority randomised controlled trial with an internal pilot, economic evaluation and nested qualitative study.
Journal article
Brady S. et al, (2024), BMJ Open, 14
-
A genome-wide association meta-analysis implicates Hedgehog and Notch signaling in Dupuytren's disease.
Journal article
Riesmeijer SA. et al, (2024), Nat Commun, 15
-
Anti-TNF (adalimumab) injection for the treatment of adults with frozen shoulder during the pain predominant stage protocol for a multi-centre, randomised, double blind, parallel group, feasibility trial
Journal article
Hopewell S. et al, (2023), NIHR Open Research, 2, 28 - 28
-
Treatments for early-stage Dupuytren’s disease: an evidence-based approach
Journal article
Nanchahal J. and Chan JK-K., (2023), Journal of Hand Surgery (European Volume), 175319342211313 - 175319342211313
-
Dupuytren's disease: a localised and accessible human fibrotic disorder.
Journal article
Layton TB. et al, (2022), Trends Mol Med
SYSTEMATIC REVIEWS
Berner JE, Pereira N, Troisi L, Will P, Nanchahal J, Jain A (2020) Journal of Plastic, Reconstructive & Aesthetic Surgery. |
Systematic review of non-surgical treatments for early Dupuytren’s disease. Ball C, Izadi D, Verjee LS, Chan J K-K, Nanchahal J (2016) BMC Musculoskeletal Disorders. 17(1): 345 Referenced in NICE Interventional procedure review of radiation therapy for early Dupuytren’s disease 201:6 IP780/2 (IPG573) |
Standards for the Management of Open Tibial Fractures. Contribution to chapters on Prehospital and Emergency Care and Antibiotic Prophylaxis, Timing of Wound Excision, Wound Excision, Degloving Injuries, Temporary Dressings, Soft Tissue Reconstruction, Vascular Injuries, Open Fragility Fractures Eccles S, Handley R, Khan U, McFadyen I, Nanchahal J, Nayagan, S (listed alphabetically) (2020) Oxford University Press. ISBN-13: 9780198849360 |